Dr. Nastoupil on Triplet of TGR1202, Ublituximab, and Ibrutinib in CLL

Loretta J. Nastoupil, MD
Published: Thursday, Aug 10, 2017



Loretta J. Nastoupil, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses an early-phase trial looking at the triplet regimen of TGR1202, ublituximab, and ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).

This regimen does appear to be tolerated in patients, with most adverse events being grade 1 or 2, says Nastoupil. Infrequent grade 3 events included neutropenia (18%), colitis or diarrhea (3%) and pneumonia at (11%). A maximum tolerated dose has not been determined.

Though the primary endpoint of the study was assessing safety, clinical responses were also reported. The overall response rate was 83%, and was 100% in the CLL cohort, with 6 patients achieving a complete response, Nastoupil adds.


Loretta J. Nastoupil, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses an early-phase trial looking at the triplet regimen of TGR1202, ublituximab, and ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).

This regimen does appear to be tolerated in patients, with most adverse events being grade 1 or 2, says Nastoupil. Infrequent grade 3 events included neutropenia (18%), colitis or diarrhea (3%) and pneumonia at (11%). A maximum tolerated dose has not been determined.

Though the primary endpoint of the study was assessing safety, clinical responses were also reported. The overall response rate was 83%, and was 100% in the CLL cohort, with 6 patients achieving a complete response, Nastoupil adds.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x